Morgan Stanley Prometheus Biosciences, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $24 Million - $29.3 Million	231,910 Added 146.44%	390,276 $41.9 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $414,257 - $1.35 Million	-11,488 Reduced 6.76%	158,366 $17.4 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $1.09 Million - $2.28 Million	38,662 Added 29.47%	169,854 $10 Million
Q2 2022 Oct 27, 2022	BUY	$22.39 - $38.94 $1.84 Million - $3.2 Million	82,208 Added 167.83%	131,192 $3.7 Million
Q2 2022 Aug 15, 2022	BUY	$22.39 - $38.94 $1.84 Million - $3.2 Million	82,208 Added 167.83%	131,192 $3.7 Million
Q1 2022 Oct 27, 2022	SELL	$30.13 - $50.0 $2.48 Million - $4.11 Million	-82,208 Reduced 62.66%	48,984 $1.85 Million
Q1 2022 May 13, 2022	BUY	$30.13 - $50.0 $1.11 Million - $1.84 Million	36,704 Added 298.89%	48,984 $1.85 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $220,104 - $390,615	9,879 Added 411.45%	12,280 $486,000
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $50,156 - $64,730	2,401 New	2,401 $57,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.